West Pharmaceutical Q1 Non-GAAP Earnings, Net Sales Rise; Issues Q2 Guidance -- Shares Rise Pre-Bell
West Pharmaceutical Services (WST) reported Q1 non-GAAP earnings Thursday of $2.13 per diluted share, up from $1.45 a year earlier.Analysts polled by FactSet expected $1.68.Net sales for the quarter ended March 31 were $844.9 million, compared with $698 million a year earlier.Analysts surveyed by FactSet expected $780.3 million.The company expects Q2 adjusted EPS of $2.05 to $2.12. Analysts surveyed by FactSet expect $2.Revenue for the quarter is projected to be between $830 million and $850 million. Analysts polled by FactSet expect $818.4 million.For 2026, the company now expects 2026 adjusted EPS of $8.40 to $8.75, compared with its prior guidance of $7.85 to $8.20. Analysts polled by FactSet expect $8.01.Revenue for the full-year is now projected to be about $3.30 billion to $3.35 billion, compared with its earlier outlook of $3.22 billion to $3.28 billion. Analysts polled by FactSet expect $3.25 billion.Shares of the company were over 10% higher in Thursday premarket activity.Price: $310.00, Change: $+35.59, Percent Change: +12.97%
